Members

Bearden, Carrie, Ph.D.

Research

Neurogenetic disorders; neurobehavioral biomarkers of serious mental illness

Appointments

  • Professor, Departments of Psychiatry and Biobehavioral Sciences and Psychology, Semel Institute for Neuroscience and Human Behavior Brain Research Institute
  • Integrative Center for Neurobehavioral Genetics
  • Center for Autism Research and Treatment (CART)
  • Director, Center for the Assessment and Prevention of Prodromal States (CAPPS)

Biography

Her research aims to understand genetic and neurobiological risk factors for the development of early-onset neuropsychiatric disorders. Dr. Bearden’s work examines these questions through two complementary lines of research:

1) The investigation of early biomarkers that predict disease risk and trajectory in at-risk populations; and

2) Translational approaches to understanding disrupted brain circuitry in highly penetrant genetic subtypes (e.g, 22q11.2 microdeletions)

Publications

  1. Bilgrami, ZR, Castro, E, Agurto, C, Liebenthal, E, Ennis, M, Baker, JT et al.. Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiative. Schizophrenia (Heidelb). 2025;11 (1):125. doi: 10.1038/s41537-025-00669-z. PubMed PMID:41093845 PubMed Central PMC12528486.
  2. Farina, EA, Mourgues-Codern, C, Stimler, K, Kenney, J, Saxena, A, Mukhtar, H et al.. Shift in sex and age of individuals at a clinical high risk (CHR) for psychosis: relation to differences in recruitment methods and effect on sample characteristics. Schizophrenia (Heidelb). 2025;11 (1):123. doi: 10.1038/s41537-025-00663-5. PubMed PMID:41053030 PubMed Central PMC12501016.
  3. Rodriguez-Sanchez, J, Hauke, DJ, Pinotsis, D, Berndt, LCS, Oloye, H, Nicholas, SC et al.. Excitation/inhibition imbalance and conversion to psychosis in the clinical high risk syndrome: Biophysical modeling finds reduced pyramidal cell excitability across EEG paradigms. medRxiv. 2025; :. doi: 10.1101/2025.09.16.25335778. PubMed PMID:41001490 PubMed Central PMC12458603.
  4. Bello, D, Blyth, SH, Rabin, RA, Addington, J, Bearden, CE, Cadenhead, K et al.. Cannabis and Tobacco Co-Use Predicts Psychosis in Clinical High Risk Cohorts. medRxiv. 2025; :. doi: 10.1101/2025.09.19.25336202. PubMed PMID:41001470 PubMed Central PMC12458528.
  5. Addington, J, Liu, L, Chu, M, Jungert, K, Penzel, N, Pasternak, O et al.. Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program. Schizophr Bull Open. 2025;6 (1):sgaf012. doi: 10.1093/schizbullopen/sgaf012. PubMed PMID:40861307 PubMed Central PMC12377803.
Search PubMed